Phosphodiesterase type 5 inhibitors and kidney disease

  title={Phosphodiesterase type 5 inhibitors and kidney disease},
  author={Baris Afsar and Alberto Ortiz and Adrian Constantin Covic and Abduzhappar Gaipov and Tarik Esen and David Goldsmith and Mehmet Kanbay},
  journal={International Urology and Nephrology},
Chronic kidney disease (CKD) represents a worldwide health problem. Traditionally, the nephroprotective treatment for CKD aims to slow progression to end-stage renal disease and includes dietary protein restriction, correction of metabolic acidosis, and renin–angiotensin system blockers. However, current standard therapeutic options may not be enough for… CONTINUE READING